Learn more about Peter Attia’s digital program
The challenges of defining aging with Matt Kaeberlein, Ph.D.
This video clip is from episode #175 – The biology of aging, rapamycin, and other interventions that target the aging…
How does VO2 max correlate with longevity?
This video clip is from episode #176 – AMA #27: The importance of muscle mass, strength, and cardiorespiratory fitness for…
Can an annual flu vaccine reduce your risk of Alzheimer’s disease?
A recent retrospective study suggests that flu vaccines reduce risk of Alzheimer’s disease, but the study raises as many questions as it answers.
#232 ‒ Shoulder, elbow, wrist, and hand: diagnosis, treatment, and surgery of the upper extremities | Alton Barron, M.D.
“One should never make their clinical, especially surgical, decision-making on just an MRI.”‒ Alton Barron
#235 ‒ Training principles for mass and strength, changing views on nutrition, creatine supplementation, and more | Layne Norton, Ph.D.
“Most 40 year olds, 50 year olds, they have pain anyway. So I’d rather be strong and have pain than be weak and have pain.” —Layne Norton
#236 ‒ Neurodegenerative disease: pathology, screening, and prevention | Kellyann Niotis, M.D.
“When you think of brain health, it’s not just the cognitive piece, but it’s the movement piece too.” ‒ Kellyann Niotis
#244 ‒ The history of the cell, cell therapy, gene therapy, and more | Siddhartha Mukherjee
“I liken the human genome to a score of music, but a score is lifeless. There’s no music in a score, it’s just a code. You need a musician to bring it to life, and the cell is that musician.” —Sid Mukherjee
“The cholesterol paradox”: a catchy phrase for an idea with no substance
A recent study reported that hypercholesterolemia is associated with reduced mortality, but it falls short of upsetting conventional wisdom
#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
Do GLP-1 receptor agonists improve cardiovascular health independently of weight loss?
A new trial has reported that the GLP-1 receptor agonist semaglutide reduces risk of cardiovascular events in patients with obesity – but that’s not the question we ought to be asking.